Legorreta Pablo G. — SEC insider filings
SEC reporting owner CIK 1507678. 32 insider filings on record with FilingPulse; latest filed 2026-11-06.
Transaction summary — filings shown
Covers all 32 filings on record, filed 2021-05-11 to 2026-11-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 8 legs across 6 filings — 45,884,576 shares, $108,046,220 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 66.
- Largest priced transaction: purchase of 22,617,909 shares @ $2.42 ($54,735,340) in PROKIDNEY CORP., filed 2024-06-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| PROKIDNEY CORP. (PROK) | Director, 10% owner | 10 | 1 leg · 22,617,909 sh · $54,735,340 | — | 23 |
| Epizyme, Inc. (EPZM) | Director, 10% owner | 4 | 1 leg · 22,666,667 sh · $34,000,000 | — | 7 |
| Royalty Pharma plc (RPRX) | CEO, Chairman of the Board, Director | 18 | 6 legs · 600,000 sh · $19,310,880 | — | 36 |
Insider filings — Legorreta Pablo G.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-06 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 42,209 @ $0 | EDGAR |
| 2026-08-07 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 65,216 @ $0 · Gift (G): 30,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | PROKIDNEY CORP. (PROK) | Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 143,821 @ $0 | EDGAR |
| 2026-02-13 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 157,828 @ $0 | EDGAR |
| 2025-11-07 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 36,559 @ $0 | EDGAR |
| 2025-08-08 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 21,901 @ $0 · Gift (G): 60,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | PROKIDNEY CORP. (PROK) jointly with Tolerantia, LLC | Conversion (C): 3,823,996 @ $0 · Other (J): 3,823,996 @ $0 · Conversion (C): 3,823,996 (derivative) @ $0 · Conversion (C): 3,823,996 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | PROKIDNEY CORP. (PROK) | Grant/award (A): 125,862 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | Royalty Pharma plc (RPRX) | Other (J): 530,348 @ $0 · Grant/award (A): 13,356,742 (derivative) @ $0 · Other (J): 857,138 (derivative) @ $0 | EDGAR |
| 2025-05-14 | 4 | Royalty Pharma plc (RPRX) | Gift (G): 867,180 (derivative) @ $0 · Gift (G): 867,180 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 288,352 @ $0 | EDGAR |
| 2025-02-06 | 4 | PROKIDNEY CORP. (PROK) jointly with Tolerantia, LLC | Conversion (C): 532,535 @ $0 · Other (J): 532,535 @ $0 · Conversion (C): 532,535 (derivative) @ $0 · Conversion (C): 532,535 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | PROKIDNEY CORP. (PROK) jointly with Tolerantia, LLC | Purchase (P): 22,617,909 @ $2.42 | EDGAR |
| 2024-06-03 | 4 | PROKIDNEY CORP. (PROK) | Grant/award (A): 62,558 (derivative) @ $0 | EDGAR |
| 2024-02-06 | 4 | PROKIDNEY CORP. (PROK) jointly with Tolerantia, LLC | Conversion (C): 748,952 @ $0 · Other (J): 748,952 @ $0 · Conversion (C): 748,952 (derivative) @ $0 · Conversion (C): 748,952 (derivative) @ $0 | EDGAR |
| 2023-11-16 | 4 | Royalty Pharma plc (RPRX) | Gift (G): 292,190.49 @ $0 · Other (J): 383,000 @ $0 | EDGAR |
| 2023-11-01 | 4 | PROKIDNEY CORP. (PROK) jointly with Tolerantia, LLC | Conversion (C): 5,289,055 @ $0 · Other (J): 5,289,055 @ $0 · Conversion (C): 5,289,055 (derivative) @ $0 · Conversion (C): 5,289,055 (derivative) @ $0 | EDGAR |
| 2023-07-03 | 4 | PROKIDNEY CORP. (PROK) | Grant/award (A): 48,128 (derivative) @ $0 | EDGAR |
| 2023-06-28 | 4 | Royalty Pharma plc (RPRX) | Purchase (P): 130,000 @ $29.51 | EDGAR |
| 2023-06-13 | 4 | Royalty Pharma plc (RPRX) | Purchase (P): 45,000 @ $33.00 · Purchase (P): 45,000 @ $32.78 | EDGAR |
| 2023-05-24 | 4 | Royalty Pharma plc (RPRX) | Purchase (P): 150,000 @ $32.25 | EDGAR |
| 2023-05-17 | 4 | Royalty Pharma plc (RPRX) | Purchase (P): 160,388 @ $33.57 · Purchase (P): 69,612 @ $32.94 | EDGAR |
| 2023-05-15 | 4 | Royalty Pharma plc (RPRX) | Gift (G): 10,269 (derivative) @ $0 · Gift (G): 10,269 (derivative) @ $0 | EDGAR |
| 2022-08-16 | 4 | Epizyme, Inc. (EPZM) jointly with RP Management, LLC, RPI Finance Trust, Royalty Pharma Investments 2019 ICAV | Code (U): 31,933,334 · Disposition to issuer (D): 8,060 (derivative) @ $0 · Disposition to issuer (D): 8,994 (derivative) @ $0 | EDGAR |
| 2022-07-13 | 4 | PROKIDNEY CORP. (PROK) jointly with Tolerantia, LLC | Grant/award (A): 94,677,968 (derivative) @ $0 · Grant/award (A): 94,677,968 (derivative) @ $0 · Grant/award (A): 10,500,000 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | Epizyme, Inc. (EPZM) jointly with RP Management, LLC, RPI Finance Trust, Royalty Pharma Investments 2019 ICAV | Grant/award (A): 41,006 (derivative) @ $0.56 · Grant/award (A): 8,994 (derivative) @ $0 | EDGAR |
| 2022-04-15 | 4/A | Royalty Pharma plc (RPRX) | Grant/award (A): 1,719,074 (derivative) @ $0 | EDGAR |
| 2022-04-15 | 4 | Royalty Pharma plc (RPRX) | Conversion (C): 493,750 @ $0 · Conversion (C): 428,420 @ $0 · Other (J): 462,031 @ $0 · Other (J): 350,000 @ $0 · Conversion (C): 49,375 (derivative) @ $0 · Conversion (C): 49,375 (derivative) @ $0 · +7 more | EDGAR |
| 2022-02-01 | 4 | Epizyme, Inc. (EPZM) jointly with RP Management, LLC, RPI Finance Trust | Purchase (P): 22,666,667 @ $1.50 | EDGAR |
| 2021-06-15 | 4 | Epizyme, Inc. (EPZM) jointly with RP Management, LLC, RPI Finance Trust | Grant/award (A): 40,559 (derivative) @ $8.53 · Grant/award (A): 8,060 (derivative) @ $0 | EDGAR |
| 2021-05-11 | 4 | Royalty Pharma plc (RPRX) | Conversion (C): 1,040,410 @ $0 · Conversion (C): 1,284,590 @ $0 · Conversion (C): 104,041 (derivative) @ $0 · Conversion (C): 128,459 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-03-08 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1507678 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs